Chemicon International, Inc. Licenses Quantum Dot Antibody Reagent Line From Quantum Dot Corporation

Chemicon International, a subsidiary of Serologicals Corporation (NASDAQ: SERO), and Quantum Dot Corporation (QDC) today announced the signing of an agreement granting Chemicon rights to market specific quantum dot-containing products for the detection of antibody-antigen interactions in immunological experiments. This agreement will add novel secondary antibody detection technologies to Chemicon's general reagents product portfolio. Researchers will be able to use these products for the study of antigen presence in a variety of tissue and cell culture samples. Chemicon is recognized as a worldwide leader in providing specific antibodies, kits and ancillary reagents for the detection of antigen targets in the neuroscience, stem cell, cancer, in vitro diagnostics, and other fields. Chemicon will offer these products through its direct sales team in North America, Australia, UK and much of Europe, as well as through its worldwide network of distributors.

Quantum Dot Corporation and collaborators have successfully demonstrated the application and benefits of quantum dot-conjugated antibodies in a variety of applications. Quantum dot (Qdot®) nano-particles are tiny semiconductor crystals that emit light brightly in a range of sharp colors. These nanometer-sized Qdot particles have unique, highly desirable properties that make them a superior detection platform for biology. When conjugated to antibodies these particles offer a unique light–based methodology for the detection of specific biochemical targets in biological samples.

"Chemicon is very pleased to be selling Chemicon-branded quantum dot secondary antibodies," said Jeffrey D. Linton, President of Chemicon. "This detection technology allows us to continue to offer superior labeling technologies to our customers, and leverages our strong position as a market-leading provider of antibodies to thousands of researchers worldwide."

"This agreement is an important step in the commercialization of our Qdot nanocrystal technology. We are happy to be able to access the significant commercial infrastructure of Chemicon to quickly expand our user base," said George S. Dunbar, President and CEO of Quantum Dot Corporation.